Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Apr-24 4:21 PM View:  | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 12-Apr-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 12-Apr-24 | Option Sale | 20,000 | $91.26 | $1,825,200.00 | (3%) 742.53K to 722.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 11-Apr-24 | Option Sale | 20,000 | $90.99 | $1,819,800.00 | (3%) 742.53K to 722.53K | |
| 15-Apr-24 4:21 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 11-Apr-24 | Option Exercise | 20,000 | $63.10 | $1,262,000.00 | 3% 722.53K to 742.53K | |
| 12-Apr-24 3:07 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 10-Apr-24 | Market Sale | 2,286 | $90.00 | $205,740.00 | (12%) 18.44K to 16.16K | 6% |
| 01-Apr-24 4:54 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 28-Mar-24 | Market Sale | 24,602 | $88.34 | $2,173,340.00 | (31%) 80.46K to 55.86K | 4% |
| 20-Mar-24 5:13 PM View: | Slamon Dennis Director | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Option Exercise | 10,000 | $79.70 | $797,000.00 | 32% 30.81K to 40.81K | 6% |
| 19-Mar-24 8:55 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Payment of Exercise | 372 | $83.87 | $31,199.60 | (2%) 18.81K to 18.44K | |
| 20-Mar-24 5:13 PM View: | Slamon Dennis Director | BioMarin Pharmaceutical Inc. (BMRN) | 18-Mar-24 | Payment of Exercise | 9,510 | $83.81 | $797,033.00 | (23%) 40.81K to 31.3K | (< 1%) |
| 19-Mar-24 8:48 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 11,400 | -- | -- | 14% 81.25K to 92.65K | |
| 19-Mar-24 8:50 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 10,550 | -- | -- | 12% 88.2K to 98.75K | |
| 19-Mar-24 8:53 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 10,260 | -- | -- | 11% 91.9K to 102.16K | |
| 19-Mar-24 8:55 PM View: | Burkhart Erin GVP, Chief Accounting Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 4,720 | -- | -- | 33% 14.09K to 18.81K | |
| 19-Mar-24 8:48 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 20,789 | $83.87 | $1,743,570.00 | (22%) 92.65K to 71.86K | |
| 19-Mar-24 8:36 PM View: | Ajer Jeffrey Robert EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 22,580 | $83.87 | $1,893,780.00 | (24%) 94.05K to 71.47K | (< 1%) |
| 19-Mar-24 8:50 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 20,424 | $83.87 | $1,712,960.00 | (21%) 98.75K to 78.33K | |
| 19-Mar-24 8:53 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 21,699 | $83.87 | $1,819,900.00 | (21%) 102.16K to 80.46K | |
| 19-Mar-24 8:42 PM View: | Hardy Alexander Chief Executive Officer Director | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 32,780 | -- | -- | 28% 115.37K to 148.15K | |
| 19-Mar-24 8:46 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Grant | 18,240 | -- | -- | 9% 212.12K to 230.36K | |
| 19-Mar-24 8:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 85,209 | $83.87 | $7,146,480.00 | (11%) 807.74K to 722.53K | (< 1%) |
| 19-Mar-24 8:46 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 15-Mar-24 | Payment of Exercise | 33,485 | $83.87 | $2,808,390.00 | (15%) 230.36K to 196.87K | |
| 07-Mar-24 5:35 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 06-Mar-24 | Market Sale | 1,000 | $86.71 | $86,713.00 | (< 1%) 808.74K to 807.74K | 3% |
| 07-Mar-24 5:35 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 05-Mar-24 | Market Sale | 1,000 | $85.51 | $85,510.00 | (< 1%) 809.74K to 808.74K | 1% |
| 07-Mar-24 6:54 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 05-Mar-24 | Market Sale | 35,341 | $85.18 | $3,010,400.00 | (14%) 247.46K to 212.12K | < 1% |
| 07-Mar-24 5:32 PM View: | Ajer Jeffrey Robert EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 05-Mar-24 | Market Sale | 4,000 | $87.07 | $348,280.00 | (4%) 98.05K to 94.05K | 3% |
| 29-Feb-24 5:12 PM View: | Ajer Jeffrey Robert EVP, Chief Commercial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 37,243 | -- | -- | 61% 60.8K to 98.05K | |
| 29-Feb-24 5:10 PM View: | Fuchs Henry J President, Worldwide R&D | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 53,204 | -- | -- | 27% 194.25K to 247.46K | |
| 29-Feb-24 5:05 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 143,601 | -- | -- | 22% 667.13K to 810.74K | |
| 29-Feb-24 5:18 PM View: | Mueller Brian EVP, Chief Financial Officer | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 35,125 | -- | -- | 76% 46.12K to 81.25K | |
| 29-Feb-24 5:05 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Sale | 1,000 | $90.35 | $90,350.00 | (< 1%) 810.74K to 809.74K | |
| 29-Feb-24 5:14 PM View: | Guyer Charles Greg EVP, Chief Technical Officer | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 36,187 | -- | -- | 70% 52.01K to 88.2K | |
| 29-Feb-24 5:16 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 27-Feb-24 | Grant | 36,187 | -- | -- | 65% 55.71K to 91.9K | |
| 12-Feb-24 5:20 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-Feb-24 | Option Sale | 15,000 | $88.28 | $1,324,200.00 | (2%) 682.13K to 667.13K | |
| 12-Feb-24 5:20 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-Feb-24 | Option Exercise | 15,000 | $63.10 | $946,500.00 | 2% 667.13K to 682.13K | |
| 12-Feb-24 5:20 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 08-Feb-24 | Option Sale | 15,000 | $89.77 | $1,346,550.00 | (2%) 682.13K to 667.13K | |
| 12-Feb-24 5:20 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 08-Feb-24 | Option Exercise | 15,000 | $63.10 | $946,500.00 | 2% 667.13K to 682.13K | |
| 12-Feb-24 5:20 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 18-Jan-24 | Acquisition (small) | 40 | $92.60 | $3,703.90 | < 1% 667.1K to 667.13K | (9%) |
| 11-Jan-24 2:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 10-Jan-24 | Option Exercise | 10,000 | $63.10 | $631,000.00 | 1% 672.7K to 682.7K | |
| 11-Jan-24 2:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 10-Jan-24 | Option Sale | 10,000 | $96.38 | $963,800.00 | (1%) 682.7K to 672.7K | |
| 11-Jan-24 2:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-Jan-24 | Option Exercise | 10,000 | $63.10 | $631,000.00 | 1% 672.7K to 682.7K | |
| 11-Jan-24 2:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 09-Jan-24 | Option Sale | 10,000 | $98.19 | $981,900.00 | (1%) 682.7K to 672.7K | |
| 11-Jan-24 2:40 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 08-Jan-24 | Acquisition (small) | 50 | $99.05 | $4,952.59 | < 1% 672.64K to 672.7K | |
| 23-Jan-24 7:47 PM View: | Meier Richard A Director | BioMarin Pharmaceutical Inc. (BMRN) | 08-Jan-24 | Gift | 3,000 | -- | -- | (3%) 115.55K to 112.55K | |
| 28-Dec-23 1:13 PM View: | Enyedy Mark J Director | BioMarin Pharmaceutical Inc. (BMRN) | 27-Dec-23 | Grant | 2,180 | -- | -- | 100% 0 to 2.18K | |
| 28-Dec-23 1:18 PM View: | Bodem Barbara W. Director | BioMarin Pharmaceutical Inc. (BMRN) | 27-Dec-23 | Grant | 2,180 | -- | -- | 100% 0 to 2.18K | |
| 28-Dec-23 1:03 PM View: | Countouriotis Athena Director | BioMarin Pharmaceutical Inc. (BMRN) | 27-Dec-23 | Grant | 2,180 | -- | -- | 100% 0 to 2.18K | |
| 22-Dec-23 5:14 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-Dec-23 | Option Exercise | 10,000 | $63.10 | $631,000.00 | 1% 672.64K to 682.64K | |
| 22-Dec-23 5:14 PM View: | Bienaime Jean Jacques Director | BioMarin Pharmaceutical Inc. (BMRN) | 21-Dec-23 | Option Sale | 10,000 | $93.99 | $939,900.00 | (1%) 682.64K to 672.64K | |
| 14-Dec-23 6:18 PM View: | Davis George Eric EVP, Chief Legal Officer | BioMarin Pharmaceutical Inc. (BMRN) | 13-Dec-23 | Private Sale | 13,764 | $95.30 | $1,311,710.00 | (20%) 69.47K to 55.71K | |
| 05-Dec-23 5:13 PM View: | Hardy Alexander Chief Executive Officer Director | BioMarin Pharmaceutical Inc. (BMRN) | 01-Dec-23 | Grant | 115,371 | -- | -- | 100% 0 to 115.37K |
